Gregory L. Shiferman - 01 Nov 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Senior Vice President, General Counsel and Secretary
Signature
Brandon Marsh, attorney in fact for Gregory Shiferman
Issuer symbol
SAGE
Transactions as of
01 Nov 2024
Net transactions value
$0
Form type
4
Filing time
01 Nov 2024, 16:24:22 UTC
Next filing
27 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +5,000 +33% $0.000000 19,967 01 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to buy) Award $0 +10,000 $0.000000 10,000 01 Nov 2024 Common Stock 10,000 $6.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 5,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on November 1, 2025, subject to the Reporting Person's continued service.
F2 The option was granted on November 1, 2024, pursuant to the Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on November 1, 2025, and the remainder vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Remarks:

Senior Vice President, General Counsel and Secretary